Status:
UNKNOWN
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Lead Sponsor:
Sheba Medical Center
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis before starting ...
Detailed Description
Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate. The gait analysis w...
Eligibility Criteria
Inclusion
- Clinical diagnosis of multiple sclerosis
- EDSS less than 5.5
- No cognitive disability
Exclusion
- EDSS over 5.5
- Inability to cooperate with gait analysis
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00331747
Start Date
May 1 2006
Last Update
July 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Sclerosis Center, Sheba Medical Center
Tel Litwinsky, Israel, 52621